

CONTENTS VOL. 12, No. 1, 1993

RESEARCH ADVANCES IN THE CELL BIOLOGY OF PROSTATE CANCER

Prostatic cancer: an overview J.T. Isaacs	1
Molecular and cellular markers for metastatic prostate cancer C.W. Rinker-Schaeffer, W.B. Isaacs, and J.T. Isaacs	3
Rodent models for targeted oncogenesis of the prostate gland R. Buttyan and K. Slawin	11
<i>In vivo</i> and <i>in vitro</i> approaches to study metastasis in human prostatic cancer C. Lee, D.H. Shevrin and J.M. Kozlowski	21
Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: Biological significance and clinical implications L.A. Girolodi and J.A. Schalken	29
Autocrine factors, type IV collagenase secretion and prostatic cancer cell invasion M.E. Stearns and M. Stearns	39
Cellular motility and prostatic carcinoma metastases J.L. Mohler	53
Announcement	69
Instructions for authors	71

CONTENTS VOL. 12, No. 2, 1993

BIOREDUCTIVE DRUGS FOR CANCER THERAPY

The experimental development of bioreductive drugs and their role in cancer therapy P. Workman and I.J. Stratford	73
DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C D. Ross, D. Siegel, H. Beall, A.S. Prakash, R.T. Mulcahy, and N.W. Gibson	83
NAD(P)H:Quinone oxidoreductase ₁ (DT-diaphorase) expression in normal and tumor tissues M. Belinsky and A.K. Jaiswal	103
Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent L.H. Patterson	119
Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs) W.A. Denny and W.R. Wilson	135
Cellular approaches to bioreductive drug mechanisms A.M. Rauth, R.S. Marshall, and B.L. Kuehl	153
Cellular pharmacology of quinone bioreductive alkylating agents S. Rockwell, A.C. Sartorelli, M. Tomasz, and K.A. Kennedy	165
Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to <i>in vivo</i> methods of evaluation J.C.M. Bremner	177
The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT) R.J. Knox, F. Friedlos, and M.P. Boland	195
Instructions for authors	213

CONTENTS VOL. 12, Nos. 3/4, 1993

GROWTH FACTORS: MULTIFUNCTIONAL MEDIATORS OF MALIGNANT TUMOR GROWTH AND PROGRESSION

Overview – Growth factors as mediators of malignant tumor progression R.S. Kerbel	215
Growth factor independence and growth regulatory pathways in human melanoma development U. Rodeck	219
Escape from negative regulation of growth by transforming growth factor β and from the induction of apoptosis by the dietary agent sodium butyrate may be important in colorectal carcinogenesis A. Hague, A.M. Manning, J.W.J. van der Stappen and C. Paraskeva	227
Transforming growth factor beta and the cell surface in tumor progression M.J. Newman	239
EGF receptor in neoplasia and metastasis K. Khazaie, V. Schirmacher and R.B. Lichtner	255
The role of growth regulatory aberrations in progression on human colon carcinoma G.M. Howell, L. Sun, B.L. Ziober, S. Ping Wu and M.G Brattain	275
Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer J.L. Ware	287
Vascular permeability factor (VPF, VEGF) in tumor biology D.R. Senger, L. Van De Water, L.F. Brown, J.A. Nagy, K.-T. Yeo, T.-K. Yeo, B. Berse, R.W. Jackman, A.M. Dvorak and H.F. Dvorak	303
Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis G.L. Nicolson	325
Paracrine growth regulation of human colon carcinoma organ-specific metastasis R. Radinsky	345
Volume Contents	363
Instructions for authors	367